Screening Libraries

Product Data Sheet

SORT-PGRN interaction inhibitor 1

Cat. No.: HY-115213 CAS No.: 100957-85-5 Molecular Formula: $C_{15}H_{18}N_{2}O_{2}$ Molecular Weight: 258.32

Target: Neurotensin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (387.12 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.8712 mL	19.3558 mL	38.7117 mL
	5 mM	0.7742 mL	3.8712 mL	7.7423 mL
	10 mM	0.3871 mL	1.9356 mL	3.8712 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.68 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-programulin interaction with an IC $_{50}$ of 2 μ M $^{[1]}$.
IC ₅₀ & Target	IC50: 2 μ M (Sortilin-progranulin interaction) $^{[1]}$
In Vitro	SORT-PGRN interaction inhibitor 1 (Compound 2) with sufficient potency and physicochemical properties to enable co- crystallization with sortilin ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES					
[1]. Shawn J Stachel, et al. Ider	ntification of potent inhibito	rs of the sortilin-progranulin inte	eraction. Bioorg Med Chem Le	tt. 2020 Sep 1;30(17):127403.	
		not been fully validated for n			
	Tel: 609-228-6898	Fax: 609-228-5909 1 Deer Park Dr, Suite Q, Monn	E-mail: tech@MedCl		

Page 2 of 2 www.MedChemExpress.com